CN1857442A - Preparation and application of ligustrazine and its salt composition - Google Patents
Preparation and application of ligustrazine and its salt composition Download PDFInfo
- Publication number
- CN1857442A CN1857442A CN 200610046079 CN200610046079A CN1857442A CN 1857442 A CN1857442 A CN 1857442A CN 200610046079 CN200610046079 CN 200610046079 CN 200610046079 A CN200610046079 A CN 200610046079A CN 1857442 A CN1857442 A CN 1857442A
- Authority
- CN
- China
- Prior art keywords
- total
- ligustrazine
- content
- flavone
- radix
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to compound preparation with ligustrazine and its salt composition as main component for treating cardiac and cerebral vascular diseases. The ligustrazine and its salt composition contains ligustrazine and its salt in 1-99 wt%, and total erigeron braviscapus flavone, total haw phenolic acid, total gingko leaf flavone, sowthistle-leaf ixeris flavonid, safflower flavonid, kudzu vine root flavonid, general peony glycosideor, seabuckthorn flavonid, total astragalus flavone and saponin, or ginsenoside in 1-99 wt%, and is compounded with pharmaceutically acceptable supplementary material to prepare pharmaceutically acceptable preparations. The medicine of the present invention is used in preventing and treating cardiac and cerebral vascular diseases, senile dementia, and other diseases.
Description
Technical field:
The present invention relates to a kind of compound preparation of the treatment cardiovascular and cerebrovascular disease based on ligustrazine (comprising various mineral acids and acylates such as hydrochlorate, phosphate) compositions.And the application of various preparations in pharmaceutical field that utilizes the inventive method to obtain, the particularly application in the medicine of preparation control cardiovascular and cerebrovascular disease, senile dementia, cerebral infarction, cerebral ischemia and other various diseases of causing by cerebral ischemia thereof etc.Make a distinction between the important and the lesser one in the full side of medicine of the present invention, compatibility is proper, and complementation is short mutually.
Background technology:
Rhizoma Chuanxiong, Herba Erigerontis, Fructus Crataegi, Semen Ginkgo, Herba Ixeritis Sonchifoliae, Flos Carthami, Radix Puerariae, Radix Paeoniae Rubra, the Radix Paeoniae Alba, Fructus Hippophae, the Radix Astragali, Radix Ginseng etc. all are China's conventional Chinese medicines, its medicine as the treatment cardiovascular and cerebrovascular disease has basis of clinical application widely and long clinical application history, and evident in efficacy.Modern pharmacology studies show that one of main effective ingredient in Rhizoma Chuanxiong ligustrazine and salt thereof have effects such as antiplatelet aggregation, expansion small artery, microcirculation improvement, cerebral circulation; Breviscapine can reduce Peripheral resistance, reduce myocardial oxygen consumption, promote collateral circulation, anticoagulant, improve cardiovascular and cerebrovascular circulation, increase effects such as cardiovascular and cerebrovascular vessel blood flow; Total phenolic acids of Caulis Crataegi and Folium Crataegi improves significantly to the blood ability of penetrating, the oxygen metabolism effect tool of heart, can significantly increase cardiac output and cardiac output, increases venous oxygen content, reduces myocardial oxygen consumption, improves the blood supply oxygen supply of cardiac muscle; Folium Ginkgo total flavones and Herba Ixeritis Sonchifoliae total flavones have effects such as blood vessel dilating, blood flow increasing, blood viscosity lowering, quickening blood flow rate, anti-hypoxia; Flos Carthami total flavone has effects such as coronary artery dilator, coronary blood flow increasing, microcirculation improvement, blood fat reducing, blood pressure lowering; Radix Puerariae total flavones (its main component is a puerarin) has promoting blood circulation and stopping pain, expansion is normal and the coronary vasodilator of spasm, lax vascular smooth muscle, improve ischemic region the cardiac muscle power supply, reduce the myocardium lactic acid that causes because of ischemia generation, reduce oxygen consumption, improve effect such as myocardial metabolism; Peoniflorin have promote learning memory disorder due to learning and memory, the antagonism scopolamine, significantly improve learning memory disorder due to the cerebral ischemia re-pouring, improve effects such as body microcirculating state, blood viscosity lowering, the inductive platelet aggregation of inhibition ADP; Radix Ginseng has blood circulation promoting and blood stasis dispelling, reduction myocardial oxygen consumption, raising brain oxygen-supplying amount, promotes cerebral nerve growth, two-ways regulation, rises multiple important physical activity such as blood pressure, antitumor, enhance immunity; Radix Astragali total flavones and total saponins thereof have the myocardium shrinkage function of improvement, dwindle myocardial infarction area, alleviate myocardial damage, improve myocardial ischemia, protect effects such as cardiovascular and cerebrovascular vessel, microcirculation improvement, antiviral property myocarditis.Modern clinical research shows that Fructus Hippophae total flavones has curative effect preferably for angina pectoris, coronary heart disease.
How to overcome the shortcoming of taking single medicinal material, reasonable compatibility, short complementary mutually, make it to become effective good recipe of treatment diseases of cardiovascular and cerebrovascular systems, making it to bring into play the best use of at aspect such as improve cardio-cerebrovascular function and control aging of brain, raise immunity, slow down aging, improve the quality of living is its maximum difficult point.
Summary of the invention:
Purpose of the present invention, be defective and the deficiency that exists at above-mentioned prior art, provide a kind of and can overcome the shortcoming of taking single medicinal material, reasonable compatibility, short complementary mutually, make it to become effective good recipe of treatment diseases of cardiovascular and cerebrovascular systems, make it that the best use of is brought into play in the aspect improving cardio-cerebrovascular function and control aging of brain, raise immunity, slow down aging, improve the quality of living etc.
Further aim of the present invention provides ligustrazine and (comprises hydrochlorate, various mineral acids such as phosphate and acylate) compositions (is the compositions of ligustrazine and salt thereof and breviscapine, the compositions of ligustrazine and salt thereof and total phenolic acids of Caulis Crataegi and Folium Crataegi, the compositions of ligustrazine and salt thereof and Folium Ginkgo total flavones, the compositions of ligustrazine and salt thereof and Herba Ixeritis Sonchifoliae total flavones, ligustrazine and salt thereof and total safflower flavone composition, ligustrazine and salt thereof and pueraria flavonid composition, the compositions of ligustrazine and salt thereof and Radix Paeoniae Alba total glycosides, the compositions of ligustrazine and salt thereof and Fructus Hippophae total flavones, the compositions of ligustrazine and salt thereof and Radix Astragali total flavones and total saponins, the compositions of ligustrazine and salt thereof and Radix Ginseng total saponins) and the application of preparation in pharmaceutical field, particularly be used to prevent and treat cardiovascular and cerebrovascular disease in preparation, senile dementia, other dysfunction that cerebral ischemia causes, the medicine of the anti-ageing disease of waiting for a long time.
The present invention is implemented by following technical proposals.
The present invention relates to a kind of is the method for the compound preparation of main preparation control cardiovascular and cerebrovascular disease, senile dementia, cerebral ischemia and other various diseases of being caused by cerebral ischemia thereof etc. by ligustrazine (comprising various mineral acids such as hydrochlorate, sulfate and acylate) compositions, it is characterized in that this method comprises following content:
(1) calculates according to composition by weight and get 99～1 parts of 1～99 part of ligustrazine (comprising various mineral acids and acylates such as hydrochlorate, phosphate) and breviscapines (content of flavone is 20%～100% in the breviscapine) respectively, respectively or mix the suitable adjuvant of back adding such as antioxidant, chelating agent, filler, framework material etc. and make said various preparations on any pharmaceutics.As be used for can be made into forms such as corresponding tablet, granule, capsule when oral; Make powder pin, freeze-dried powder, transfusion etc. when being used to inject.
(2) calculate according to composition by weight and get 99～1 parts of 1～99 part of ligustrazine (comprising various mineral acids and acylates such as hydrochlorate, phosphate) and total phenolic acids of Caulis Crataegi and Folium Crataegi (content of total phenolic acid is 20%～100% in the total phenolic acids of Caulis Crataegi and Folium Crataegi) respectively, respectively or mix the suitable adjuvant of back adding such as antioxidant, chelating agent, filler, framework material etc. and make said various preparations on any pharmaceutics.As be used for can be made into forms such as corresponding tablet, granule, capsule when oral; Make powder pin, freeze-dried powder, transfusion etc. when being used to inject.
(3) calculate according to composition by weight and get 99～1 parts of 1～99 part of ligustrazine (comprising various mineral acids and acylates such as hydrochlorate, phosphate) and Folium Ginkgo total flavoness (content of total flavone is 20%～100% in the Folium Ginkgo total flavones) respectively, respectively or mix the suitable adjuvant of back adding such as antioxidant, chelating agent, filler, framework material etc. and make said various preparations on any pharmaceutics.As be used for can be made into forms such as corresponding tablet, granule, capsule when oral; Make powder pin, freeze-dried powder, transfusion etc. when being used to inject.
(4) calculate according to composition by weight and get 99～1 parts of 1～99 part of ligustrazine (comprising various mineral acids and acylates such as hydrochlorate, phosphate) and Herba Ixeritis Sonchifoliae total flavoness (content of total flavone is 20%～100% in the Herba Ixeritis Sonchifoliae total flavones) respectively, respectively or mix the suitable adjuvant of back adding such as antioxidant, chelating agent, filler, framework material etc. and make said various preparations on any pharmaceutics.As be used for can be made into forms such as corresponding tablet, granule, capsule when oral; Make powder pin, freeze-dried powder, transfusion etc. when being used to inject.
(5) calculate according to composition by weight and get 99～1 parts of 1～99 part of and Flos Carthami total flavones (content of total flavone is 20%～100% in the Flos Carthami) of ligustrazine (comprising various mineral acids and acylates such as hydrochlorate, phosphate) respectively, respectively or mix the back and add suitable adjuvant such as antioxidant, chelating agent, filler, framework material etc. and make said various preparations on any pharmaceutics.As be used for can be made into forms such as corresponding tablet, granule, capsule when oral; Make powder pin, freeze-dried powder, transfusion etc. when being used to inject.
(6) calculate according to composition by weight and get 1～99 part of ligustrazine (comprising various mineral acids and acylates such as hydrochlorate, phosphate) and Radix Puerariae total flavones respectively (content of total flavone is 20%～100% in the Radix Puerariae total flavones, comprise that also content reaches the puerarin more than 90%) 99～1 parts, respectively or mix the back and add suitable adjuvant such as antioxidant, chelating agent, filler, framework material etc. and make said various preparations on any pharmaceutics.As be used for can be made into forms such as corresponding tablet, granule, capsule when oral; Make powder pin, freeze-dried powder, transfusion etc. when being used to inject.
(7) calculate according to composition by weight and get 1～99 part of ligustrazine (comprising various mineral acids and acylates such as hydrochlorate, phosphate) respectively and Radix Paeoniae Alba total glycosides (comprises Radix Paeoniae Rubra total glycosides and Radix Paeoniae Alba total glucosides, wherein the content of Radix Paeoniae Alba total glycosides is 20%～100%) 99～1 parts, respectively or mix the back and add suitable adjuvant such as antioxidant, chelating agent, filler, framework material etc. and make said various preparations on any pharmaceutics.As be used for can be made into forms such as corresponding tablet, granule, capsule when oral; Make powder pin, freeze-dried powder, transfusion etc. when being used to inject.
(8) calculate according to composition by weight and get 99～1 parts of 1～99 part of ligustrazine (comprising various mineral acids and acylates such as hydrochlorate, phosphate) and Fructus Hippophae total flavoness (content of total flavone is 20%～100% in the Fructus Hippophae total flavones) respectively, respectively or mix the suitable adjuvant of back adding such as antioxidant, chelating agent, filler, framework material etc. and make said various preparations on any pharmaceutics.As be used for can be made into forms such as corresponding tablet, granule, capsule when oral; Make powder pin, freeze-dried powder, transfusion etc. when being used to inject.
(9) calculate according to composition by weight and get 1～99 part of ligustrazine (comprising various mineral acids and acylates such as hydrochlorate, phosphate) and Radix Astragali total flavones and total saponins respectively (content of total flavone is 20%～90% in Radix Astragali total flavones and the total saponins, the content of total saponins is 10%～90%) 99～1 parts, respectively or mix the back and add suitable adjuvant such as antioxidant, chelating agent, filler, framework material etc. and make said various preparations on any pharmaceutics.As be used for can be made into forms such as corresponding tablet, granule, capsule when oral; Make powder pin, freeze-dried powder, transfusion etc. when being used to inject.
(10) calculate according to composition by weight and get 1～99 part of ligustrazine (comprising various mineral acids and acylates such as hydrochlorate, phosphate) respectively and Radix Ginseng total saponins (comprises Radix Ginseng aerial parts total saponins, wherein the content of total saponins should be 20%～100%) 99～1 parts, respectively or mix the back and add suitable adjuvant such as antioxidant, chelating agent, filler, framework material etc. and make said various preparations on any pharmaceutics.As be used for can be made into forms such as corresponding tablet, granule, capsule when oral; Make powder pin, freeze-dried powder, transfusion etc. when being used to inject.
The specific embodiment
The following examples can help those skilled in the art more fully to understand the present invention.But do not limit the present invention in any way.
Embodiment 1 ligustrazine breviscapine frozen dry powder
Get ligustrazine salt hydrochlorate 1.0g respectively, breviscapine 1.5g mixes the back with an amount of water for injection dissolving, adds 16g mannitol, after the dissolving, be diluted to 200ml, filter with water for injection, fill, lyophilizing adopts conventional injectable powder preparation method can obtain 100 freeze-dried powders.
Embodiment 2 ligustrazine Fructus Crataegi freeze-dried powders
Get ligustrazine salt hydrochlorate 1.5g respectively, total phenolic acids of Caulis Crataegi and Folium Crataegi 1.0g mixes the back with an amount of water for injection dissolving, adds 16g mannitol, after the dissolving, be diluted to 200ml, filter with water for injection, fill, lyophilizing adopts conventional injectable powder preparation method can obtain 100 freeze-dried powders.
Embodiment 3 ligustrazine Folium Ginkgo lyophilized powder pins
Get ligustrazine salt hydrochlorate 1.0g respectively, Folium Ginkgo total flavones 2.0g mixes the back with an amount of water for injection dissolving, adds 16g mannitol, after the dissolving, be diluted to 200ml, filter with water for injection, fill, lyophilizing adopts conventional injectable powder preparation method can obtain 100 freeze-dried powders.
Embodiment 4 ligustrazine Ixers sonchifolia freeze-dried powders
Get ligustrazine salt hydrochlorate 1.0g respectively, Herba Ixeritis Sonchifoliae total flavones 1.5g mixes the back with an amount of water for injection dissolving, adds 16g mannitol, after the dissolving, be diluted to 200ml, filter with water for injection, fill, lyophilizing adopts conventional injectable powder preparation method can obtain 100 freeze-dried powders.
Embodiment 5 ligustrazine Radix Paeoniae freeze-dried powders
Get ligustrazine salt hydrochlorate 1.0g respectively, Radix Paeoniae Alba total glycosides 2.0g mixes the back with an amount of water for injection dissolving, adds 16g mannitol, after the dissolving, be diluted to 200ml, filter with water for injection, fill, lyophilizing adopts conventional injectable powder preparation method can obtain 100 freeze-dried powders.
Embodiment 6 ligustrazine Flos Carthami freeze-dried powders
Get ligustrazine salt hydrochlorate 1.5g respectively, Flos Carthami total flavone 2.0g mixes the back with an amount of water for injection dissolving, adds 16g mannitol, after the dissolving, be diluted to 200ml, filter with water for injection, fill, lyophilizing adopts conventional injectable powder preparation method can obtain 100 freeze-dried powders.
Embodiment 7 ligustrazine Radix Puerariae freeze-dried powders
Get ligustrazine salt hydrochlorate 2.0g respectively, Radix Puerariae total flavones 1.0g mixes the back with an amount of water for injection dissolving, adds 16g mannitol, after the dissolving, be diluted to 200ml, filter with water for injection, fill, lyophilizing adopts conventional injectable powder preparation method can obtain 100 freeze-dried powders.
Embodiment 8 ligustrazine Fructus Hippophae freeze-dried powders
Get ligustrazine salt hydrochlorate 1.5g respectively, Fructus Hippophae total flavones 1.0g mixes the back with an amount of water for injection dissolving, adds 16g mannitol, after the dissolving, be diluted to 200ml, filter with water for injection, fill, lyophilizing adopts conventional injectable powder preparation method can obtain 100 freeze-dried powders.
Embodiment 9 ligustrazine Radix Astragali freeze-dried powders
Get ligustrazine salt hydrochlorate 1.5g respectively, Radix Astragali total flavones and total saponins 3.0g mix the back with an amount of water for injection dissolving, add 16g mannitol, after the dissolving, be diluted to 200ml, filter with water for injection, fill, lyophilizing adopts conventional injectable powder preparation method can obtain 100 freeze-dried powders.
The ginseng freeze-dried powder pin of embodiment 10 ligustrazine
Get ligustrazine salt hydrochlorate 1.0g respectively, Radix Ginseng total saponins 3.0g mixes the back with an amount of water for injection dissolving, adds 16g mannitol, after the dissolving, be diluted to 200ml, filter with water for injection, fill, lyophilizing adopts conventional injectable powder preparation method can obtain 100 freeze-dried powders.
Embodiment 11 ligustrazine breviscapine capsules
Get ligustrazine salt hydrochlorate 10g respectively, breviscapine total flavones 25g, starch 150g adopts conventional capsule preparation method thereof can make 1000 capsules after mixing.
Embodiment 12 ligustrazine Folium Ginkgo capsule
Get ligustrazine salt hydrochlorate 10g respectively, Folium Ginkgo total flavones 30g, starch 150g adopts conventional capsule preparation method thereof can make 1000 capsules after mixing.
Embodiment 13 ligustrazine Fructus Crataegi capsules
Get ligustrazine salt hydrochlorate 15g respectively, total phenolic acids of Caulis Crataegi and Folium Crataegi 25g, starch 150g adopts conventional capsule preparation method thereof can make 1000 capsules after mixing.
Embodiment 14 ligustrazine Herba Ixeritis Sonchifoliae capsules
Get ligustrazine salt hydrochlorate 10g respectively, Herba Ixeritis Sonchifoliae total flavones 15g, starch 150g adopts conventional capsule preparation method thereof can make 1000 capsules after mixing.
Embodiment 15 ligustrazine Radix Paeoniae capsules
Get ligustrazine salt hydrochlorate 10g respectively, Radix Paeoniae Alba total glycosides 35g, starch 150g adopts conventional capsule preparation method thereof can make 1000 capsules after mixing.
Embodiment 16 ligustrazine safflower capsules
Get ligustrazine salt hydrochlorate 15g respectively, Flos Carthami total flavone 10g, starch 150g adopts conventional capsule preparation method thereof can make 1000 capsules after mixing.
Embodiment 17 ligustrazine radix puerariae capsules
Get ligustrazine salt hydrochlorate 10g respectively, Radix Puerariae total flavones 25g, starch 150g adopts conventional capsule preparation method thereof can make 1000 capsules after mixing.
Embodiment 18 ligustrazine Fructus Hippophae capsules
Get ligustrazine salt hydrochlorate 10g respectively, Fructus Hippophae total flavones 20g, starch 150g adopts conventional capsule preparation method thereof can make 1000 capsules after mixing.
Embodiment 19 ligustrazine Radix Astragali capsules
Get ligustrazine salt hydrochlorate 10g respectively, Radix Astragali total flavones and total saponins 35g, starch 150g adopts conventional capsule preparation method thereof can make 1000 capsules after mixing.
Embodiment 20 ligustrazine Panax Capsule
Get ligustrazine salt hydrochlorate 10g respectively, Radix Ginseng total saponins 30g, starch 150g adopts conventional capsule preparation method thereof can make 1000 capsules after mixing.
The extraction of embodiment 21 Radix Astragali total saponinss, Radix Ginseng total saponins, Radix Paeoniae Alba total glycosides
(1) take by weighing the Radix Astragali or Radix Ginseng or Radix Paeoniae 1Kg, water or variable concentrations alcohol (comprising ethanol, methanol etc.) extract 1～3 time (the solvent consumption are 15Kg～30Kg), be evaporated to 0.5～1L, adds 1～4L ethanol, filters, and reclaims ethanol to there not being the alcohol flavor.Concentrate with suitable quantity of water dissolving (100～1000ml), with organic solvent degreasing (comprise petroleum ether, chloroform, ethyl acetate etc., hyposynchronization also can save), n-butanol extraction (comprising n-amyl alcohol etc.), reclaim get final product behind the n-butyl alcohol saponin slightly.
(2) take by weighing the Radix Astragali or Radix Ginseng or Radix Paeoniae 1Kg, water or different concentration ethanol are extracted 1～3 time (the solvent consumption are 15Kg～30Kg), be evaporated to 0.5～1L, adds 1～4L ethanol, filters, and reclaims ethanol to there not being the alcohol flavor.With suitable quantity of water dissolving (100～1000ml), (comprise polarity, middle polarity and nonpolar macroporous adsorption resin through the separation of macroporous adsorbent resin chromatography post, the ratio of the consumption of resin and crude drug is 1: 0.2～5), water, different concentration ethanol eluting successively, collect the different concentration ethanol eluting fraction, get final product the different total saponins elaboration of purity.The thick total saponins that obtains in above-mentioned (1) also can be by macroporous adsorbent resin chromatography post refining (method be the same).
The extraction of embodiment 22 Herba Erigerontis total flavones, total phenolic acids of Caulis Crataegi and Folium Crataegi, Folium Ginkgo total flavones, Herba Ixeritis Sonchifoliae total flavones, Flos Carthami total flavone, Radix Puerariae total flavones, Fructus Hippophae total flavones, Radix Astragali total flavones
(1) takes by weighing Herba Erigerontis or hawthorn stem and leaf or Semen Ginkgo stem and leaf or Herba Ixeritis Sonchifoliae or Flos Carthami or Radix Puerariae or Fructus Hippophae or Radix Astragali 1Kg, water or variable concentrations alcohol (comprising ethanol, methanol etc.) extract 1～3 time, and (the solvent consumption is 15Kg～30Kg), be evaporated to 0.5～1L, add 1～4L ethanol, filter, reclaim ethanol to there not being the alcohol flavor.Concentrate with suitable quantity of water dissolving (100～1000ml), with organic solvent degreasing (comprise petroleum ether, chloroform, etc., hyposynchronization also can save), extractions such as ethyl acetate or n-butyl alcohol or n-amyl alcohol, get final product behind the recovery organic solvent the total flavones crude product.
(2) take by weighing Herba Erigerontis or hawthorn stem and leaf or Semen Ginkgo stem and leaf or Herba Ixeritis Sonchifoliae or Flos Carthami or Radix Puerariae or Fructus Hippophae or Radix Astragali 1Kg, add 6～10 times of water gagings, regulate pH to 8～9, decocted 0.5～3 hour, filter, extract so repeatedly 1～3 time with lime cream.Merge extractive liquid, is chilled to below 70 ℃, regulates pH to 3～5 with acid (comprising mineral acid and organic acid such as acetic acid, trichloroacetic acid such as hydrochloric acid, sulphuric acid), and is static, filter get final product the total flavones crude product.
(3) take by weighing Herba Erigerontis or hawthorn stem and leaf or Semen Ginkgo stem and leaf or Herba Ixeritis Sonchifoliae or Flos Carthami or Radix Puerariae or Fructus Hippophae or Radix Astragali 1Kg, water or different concentration ethanol are extracted 1～3 time, and (the solvent consumption is 15Kg～30Kg), be evaporated to 0.5～1L, adds 1～4L ethanol, filter, reclaim ethanol to there not being the alcohol flavor.With suitable quantity of water dissolving (100～1000ml), (comprise polarity, middle polarity and nonpolar macroporous adsorption resin through the separation of macroporous adsorbent resin chromatography post, the ratio of the consumption of resin and crude drug is 1: 0.2～5), water, different concentration ethanol or methanol-eluted fractions successively, collect different concentration ethanol or methanol-eluted fractions fraction, reclaim get final product behind the solvent the different total flavones elaboration of purity.The total flavones crude product that obtains in above-mentioned (1 and 2) also can be by macroporous adsorbent resin chromatography post refining (method be the same).
(4) take by weighing Herba Erigerontis or hawthorn stem and leaf or Semen Ginkgo stem and leaf or Herba Ixeritis Sonchifoliae or Flos Carthami or Radix Puerariae or Fructus Hippophae or Radix Astragali 1Kg, water or different concentration ethanol are extracted 1～3 time, and (the solvent consumption is 15Kg～30Kg), be evaporated to 0.5～1L, adds 1～4L ethanol, filter, reclaim ethanol to there not being the alcohol flavor.With suitable quantity of water dissolving (100～1000ml), separate through the polyamide chromatographic column, water, different concentration ethanol or methanol-eluted fractions are collected different concentration ethanol or methanol-eluted fractions fraction successively, reclaim get final product behind the solvent the different total flavones elaboration of purity.The total flavones crude product that obtains in above-mentioned (1 and 2) also can be by polyamide chromatographic column refining (method be the same).
Claims (10)
1, a kind of ligustrazine (comprises hydrochlorate, various mineral acids such as phosphate and acylate) compositions, it is characterized in that being grouped into (percentage by weight) by following one-tenth: ligustrazine (comprises hydrochlorate, various mineral acids such as phosphate and acylate) 1%～99%, with Herba Erigerontis total flavones (comprising the pure product of breviscapine) 99%～1% or total phenolic acids of Caulis Crataegi and Folium Crataegi 99%～1% or Folium Ginkgo total flavones 99%～1% or Herba Ixeritis Sonchifoliae total flavones 99%～1% or Flos Carthami total flavone 99%～1% or Radix Puerariae total flavones (comprising the pure product of puerarin) 99%～1% or Radix Paeoniae Alba total glycosides (comprising Radix Paeoniae Rubra total glycosides and Radix Paeoniae Alba total glucosides) 99%～1% or Fructus Hippophae total flavones 99%～1% or Radix Astragali total flavones and total saponins 99%～1% or Radix Ginseng total saponins 99%～1%.More particularly, be meant in ligustrazine (comprising various mineral acids and acylates such as hydrochlorate, phosphate) and the said medicine combination of any one or two or more medicines, be equipped with suitable pharmaceutic adjuvant and make the pharmaceutically various preparations of acceptable.
2, according to right 1 described preparation, it is characterized in that: ligustrazine in the described composition and salt thereof comprise various mineral acids and acylates such as the hydrochlorate, phosphate of ligustrazine, and its content is 50%～100%.
3, according to right 1 described preparation, it is characterized in that: content of total flavone is 20%～100% in the Herba Erigerontis total flavones in the described composition (comprising the pure product of breviscapine); The content of total phenolic acid is 20%～100% in the total phenolic acids of Caulis Crataegi and Folium Crataegi; Content of total flavone is 20%～100% in the Folium Ginkgo total flavones; Content of total flavone is 20%～100% in the Herba Ixeritis Sonchifoliae total flavones; Content of total flavone is 20%～100% in the Flos Carthami total flavone; Content of total flavone is 20%～100% in the Fructus Hippophae total flavones.
4, according to right 1 described preparation, it is characterized in that: content of total flavone is 20%～100% in the Radix Puerariae total flavones in the described composition, comprises that also content reaches the puerarin more than 90%.
5, according to right 1 described preparation, it is characterized in that: the content of the Radix Paeoniae Alba total glycosides in the Radix Paeoniae Alba total glycosides in the described composition (comprising Radix Paeoniae Rubra total glycosides and Radix Paeoniae Alba total glucosides) is 20%～100%.
6, according to right 1 described preparation, it is characterized in that: content of total flavone is 20%～90% in Radix Astragali total flavones in the described composition and the total saponins, and the content of total saponins is 10%～90%.
7, according to right 1 described preparation, it is characterized in that: the content of total saponins should be 20%～100% in the Radix Ginseng total saponins in the described composition (comprising Radix Ginseng aerial parts total saponins).
8, according to right 1 described preparation of compositions method, it is characterized in that: it is the characteristics according to various compositionss, and the modern preparation technique that allows on the employing pharmaceutics is realized.
9, all kinds of preparations of making according to right 1 described compositions, it is characterized in that: it comprises injection type, peroral dosage form, percutaneous dosing dosage form, mucosa absorption dosage form.
10, the pharmaceutical preparation of making according to right 1 described compositions is characterized in that: be mainly used in other dysfunction, the anti-ageing disease of waiting for a long time that control cardiovascular and cerebrovascular disease, senile dementia, cerebral infarction, cerebral ischemia cause.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200610046079 CN1857442A (en) | 2006-03-17 | 2006-03-17 | Preparation and application of ligustrazine and its salt composition |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200610046079 CN1857442A (en) | 2006-03-17 | 2006-03-17 | Preparation and application of ligustrazine and its salt composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1857442A true CN1857442A (en) | 2006-11-08 |
Family
ID=37296430
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200610046079 Pending CN1857442A (en) | 2006-03-17 | 2006-03-17 | Preparation and application of ligustrazine and its salt composition |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1857442A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101474242B (en) * | 2009-01-25 | 2011-04-27 | 梁丽红 | Medicament for treating cervical vertebra and lumbar vertebra diseases without operation |
| CN102940702A (en) * | 2012-10-31 | 2013-02-27 | 成都医路康医学技术服务有限公司 | Medicine composition for treating cardia-cerebrovascular diseases |
| CN107158070A (en) * | 2017-06-09 | 2017-09-15 | 南方医科大学 | A kind of pharmaceutical composition and its production and use |
-
2006
- 2006-03-17 CN CN 200610046079 patent/CN1857442A/en active Pending
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101474242B (en) * | 2009-01-25 | 2011-04-27 | 梁丽红 | Medicament for treating cervical vertebra and lumbar vertebra diseases without operation |
| CN102940702A (en) * | 2012-10-31 | 2013-02-27 | 成都医路康医学技术服务有限公司 | Medicine composition for treating cardia-cerebrovascular diseases |
| CN107158070A (en) * | 2017-06-09 | 2017-09-15 | 南方医科大学 | A kind of pharmaceutical composition and its production and use |
| CN107158070B (en) * | 2017-06-09 | 2020-09-04 | 南方医科大学 | A kind of pharmaceutical composition and its preparation method and use |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1857473A (en) | Gynostemma pentaphylla saponin composition preparation and its preparing process | |
| CN1857472A (en) | Ginsenoside composition preparation and its preparing process | |
| CN1857388A (en) | Preparation and application of notoginseng stem and leaf total saponin composition | |
| CN1857441A (en) | Preparation and application of total salvianolic acid composition | |
| CN1899297A (en) | Schefflera venulosa extract and use in producing medicine | |
| CN100534508C (en) | Method for extracting effective sites group of smilax China root | |
| CN1857442A (en) | Preparation and application of ligustrazine and its salt composition | |
| CN1857377A (en) | Preparation and application of total safflower flavone composition | |
| CN101036708A (en) | Medicine composition for treatment of cardio-cerebralvascular disease | |
| CN1857469A (en) | Arasaponin composition preparation and its preparing process | |
| CN1857471A (en) | Tribuloside composition preparing and its preparing process | |
| CN1857395A (en) | Compound Chinese medicine composition for treating cardiac and cerebral vascular diseases | |
| CN1857439A (en) | Preparation and application of ginkgo leaf flavonid composition | |
| CN101199568A (en) | Medicament compound for treating cardiovascular disease and preparing method thereof | |
| CN1857468A (en) | Prepn and application of haw heaf total phenolic acid composition | |
| CN100464766C (en) | Medicinal composition for treating acute and chronic congestive heart failure, its preparation and use | |
| CN1730020A (en) | Method for preparing Chinese medicinal formulation for treating tumor | |
| CN1857470A (en) | Preparation and application of shortscape fleabane herb flavonid composition | |
| CN1179662C (en) | Health food composition for liver | |
| CN101077363A (en) | Traditional Chinese medicine composition for treating angina pectoris and and preparation method and application thereof | |
| CN1150839C (en) | Health food with blood pressure and blood lipoid regulating function and its production process | |
| CN1857387A (en) | Preparation and application of pueraria flavonid composition | |
| CN1883654A (en) | Pulse invigorating injection with astragalus root and preparation process thereof | |
| CN1150918C (en) | Medicine containing active components of Panax japonicum root and preparing process thereof | |
| CN103977154A (en) | Pharmaceutical composition for protecting liver |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |